[EN] HIV PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTÉASE DU VIH
申请人:MERCK SHARP & DOHME
公开号:WO2014043019A1
公开(公告)日:2014-03-20
The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
A highlyenantioselective 1,4-addition of aryltrialkoxysilanes to α,β-unsaturated esters and amides was successfully catalyzed by a chiral rhodiumcomplex generated from [Rh(cod)(MeCN)2]BF4 and (S)-BINAP.